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Abstract The protein inhibitor of activated STAT1 (PIAS1),
known to be a small ubiquitin-like modi¢er (SUMO) E3 ligase,
was found to interact with the human cytomegalovirus IE2 pro-
tein. We found that the sumoylation of IE2 was markedly en-
hanced by wild-type PIAS1 but not by a mutant containing a
Cys to Ser substitution at position 351 (C351S) within the
RING ¢nger-like domain. In target reporter gene assays,
wild-type PIAS1, but not the C351S mutant, enhanced the
IE2-mediated transactivations of viral polymerase promoter
and cellular cyclin E promoter and this augmentation required
the intact sumoylation sites of IE2. Our results suggest that
PIAS1 acts as a SUMO E3 ligase toward IE2 and that it
may regulate the transactivation function of IE2. To our knowl-
edge, IE2 is the ¢rst viral target found to be regulated by a
SUMO E3 ligase.
0 2003 Federation of European Biochemical Societies. Pub-
lished by Elsevier B.V. All rights reserved.
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1. Introduction
The human cytomegalovirus (HCMV) can cause severe dis-
ease complications and pathogenesis on infection of newborns
or immunocompromised individuals, whereas the infection of
immunocompetent individuals is usually asymptomatic. Dur-
ing the lytic-cycle infection of HCMV, a cascade of immedi-
ate^early, delayed^early, and late gene expression occurs. The
major immediate^early (MIE) proteins, 72-kDa IE1 (or IE72)
and 86-kDa IE2 (or IE86), are nuclear phosphoproteins that
are synthesized from the MIE locus by di¡erential splicing,
and are thought to act in concert to govern all downstream
gene expression [1,2].
The IE2 protein acts as a powerful non-speci¢c transacti-
vator of both viral and cellular genes as well as a repressor of
its own MIE promoter through direct DNA binding to the
MIE cis-repression signal near the 5P cap site ([3] and refer-
ences therein). IE2 interacts with components of the basal
transcription complex including TBP, TFIIB and TFIID,
and with TBP-associated factors such as TAFII110 and TA-
FII130, suggesting that IE2 has a TAF-like function [4]. IE2
also interacts with numerous transcription factors such as,
Ap-1, Egr-1, CREB, CBP, SP1-1/Pu.1, Tef-1, and P/CAF as
well as cell cycle modulators such as RB and p53 ([3] and
references therein). A recent study using a recombinant viral
genome con¢rmed that IE2 is essential for all subsequent
lytic-cycle viral gene expression in cell culture [5]. IE2 has
been shown to target adjacent to PML-associated nuclear
bodies, which are also known as PML oncogenic domains
(PODs) or as nuclear domain 10, to form immediate tran-
scription domains, and to accumulate in viral DNA replica-
tion compartments during infection [6,7].
IE2 is covalently modi¢ed by a small ubiquitin-like modi¢er
(SUMO), and sumoylation of IE2 appears to be required for
the transactivation function of IE2 [8,9]. Recently, analysis of
amino acid variations of IE2 from di¡erent HCMV strains
suggested a correlation between transactivation activity of
IE2 and its sumoylation level [10]. However, the exact role
of IE2 sumoylation in virus infection is not understood.
SUMO is covalently conjugated to the lysine residue of target
protein through a pathway distinct from but analogous to the
ubiquitin conjugation system [11^14]. SUMO is activated by
E1 enzyme (a heterodimer of SAE1/SAE2), then transferred
to an E2 conjugation enzyme (Ubc9), and attached to the O-
amino group of speci¢c lysine residues of protein substrates in
an either E3 ligase-dependent or -independent manner. To
date, three di¡erent types of E3 ligase (members of the
PIAS family, RanBP2, and Pc2) have been reported in mam-
malian cells [15^18].
The protein inhibitor of activated STAT1 (PIAS1) was orig-
inally identi¢ed as a STAT1 binding partner, which inhibits
the transactivational activity of STAT1 [19], and which is al-
most identical to the Gu/RNA helicase II-binding protein [20].
PIAS1 also acts as a cofactor of nuclear hormone receptors,
such as the androgen and glucocorticoid receptors [21^24].
Recently, PIAS1 was shown to enhance the sumoylation of
androgen receptor [25]. In mammals, ¢ve members of the
PIAS family (PIAS1, PIAS3, PIASxK, PIASxL and PIASy)
have been identi¢ed and all members of the PIAS family
and a yeast homolog, Siz1, have been shown to have
SUMO ligase activity [26,27]. In the present study, we identi-
¢ed PIAS1 as a cellular interacting partner of HCMV IE2 and
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evaluated their interaction. Our results suggest that PIAS1 has
SUMO E3 ligase activity toward IE2 and that it may regulate
the transactivation function of IE2.
2. Materials and methods
2.1. Cell culture, transfection, and virus infection
Vero and 293T cells were grown in Dulbecco’s modi¢ed Eagle’s
medium supplemented with 10% fetal calf serum. U373-SUMO-1
cells, which express SUMO-1 [28], was maintained in the same me-
dium in the presence of 0.4 mg per ml of G418. For immunoblot
analysis, 293T cells were seeded into six-well plates and DNA trans-
fection was carried out using the N,N-bis-(2-hydroxyethyl)-2-amino-
ethanesulfonic acid-bu¡ered saline (BBS) version of the calcium phos-
phate procedure. Vero cells were seeded into two-well slide chambers
[for immuno£uorescence assay (IFA)] or 12-well plates (for luciferase
assays) and DNA mixtures were introduced into cells with FuGene 6
reagents (Roche). U373-SUMO-1 cells were transfected with the BBS
reagent as above in six-well plates and super-infected with a recombi-
nant virus, HCMV(Pol-LUC), containing the extragenic Pol-LUC fu-
sion reporter gene as previously described [29].
2.2. Plasmid construction
All IE2 expression vectors in this study were generated with the IE2
cDNA derived from the Towne strain. Yeast plasmids expressing the
GAL4-DB domain (pAS1-CYH2), GAL4-DB/IE2(87^542) (pWJ1),
GAL4-DB/IE2(87^542, K175/180R) (pJHA339), and GAL4-DB/
IE2(290^542) (pCJC441) were previously described [9,30]. Plasmids
expressing GAL4-DB/IE2(S203A) (pYX141) and GAL4-DB/
IE2(K175/180R, S203A) (pYX142) were generated in a pWJ1 back-
ground using the Stratagene QuickChange site-directed mutagenesis
protocol. Plasmids expressing GAL4-DB/IE2(313^542) (pJHA211)
and GAL4-DB/IE2(346^542) (pJHA225) were generated by subclon-
ing the PCR fragment into pAS1-CYH2, and plasmids expressing the
GAL4-A domain (pACTII) and GAL4-A/SUMO-1 (pJHA313) were
previously described [9]. Plasmids expressing GAL4-A/PIAS1(wt)
(pSAN19) were generated by placing intact mouse PIAS1 cDNA
into pACTII, and plasmids expressing GST-IE2(290^542) (pHJK10),
GST-IE2(313^542) (pHJK11), and GST-IE2(346^542) (pHJK13) were
generated on pGEX-3X-derived vector, using Gateway technology
(Invitrogen). pGST-SUMO-1 was a gift from Masahiro Fujimuro
(Johns Hopkins University).
pSG5-driven expression plasmids for IE2(wt) (pJHA124),
IE2(K175/180R) (pYX104), and £ag-SUMO-1 (pJHA312) have been
described previously [9]. Plasmids expressing £ag-PIAS1(wt) (pWJ17)
and HA-IE2 (pDJK171) were generated in a pSG5 background.
Plasmids expressing the SRT-tagged PIAS1(wt) (pSAN22) and
PIAS1(C351S) (pDJK158) were also generated using Gateway tech-
nology on pSG5-SRT which contains an SRT tag [31]. Reporter plas-
mids pLA12 containing the HCMV UL54(Pol)-luciferase reporter
gene and pE(-207)-LUC containing the cyclin E-luciferase reporter
gene were previously described [9].
2.3. Yeast two-hybrid interaction assays
The yeast strain Y190 was used as the host for rapid assays for lacZ
expression using a X-Gal ¢lter assay, and for the quantitation of the
interaction between IE2 and PIAS1 using a L-galactosidase assay.
Both assays have been described previously [30].
2.4. Antibodies, IFA, and immunoblot analysis
Mouse monoclonal antibody (MAb) M2 against £ag epitope was
purchased from Sigma. Mouse MAb 8131, which detects epitopes
present in both IE1 and IE2 (exons-2 and -3), was purchased from
Chemicon (Temecula, CA, USA). Anti-HA MAb 3F10 either conju-
gated with peroxidase or labeled with £uorescein and anti-myc mouse
MAb 9E10 were purchased from Roche. Rabbit antipeptide polyclon-
al Ab (PAb) referred to as PML(C) was as described previously [29].
Mouse MAb against SRT epitope [31] was purchased from Ahram
Biosystems Inc. (Seoul, Korea).
For IFA, cells were ¢xed with 1% paraformaldehyde and perme-
abilized with 0.2% Triton X-100. All subsequent procedures were as
Fig. 1. Interaction of IE2 with PIAS1 in yeast. A: A diagram showing the domains of IE2 required for transactivation, autoregulation, and di-
merization. Two transactivation domains and two major sumoylation sites (Lys residues at positions 175 and 180) are denoted as black boxes
and encircled S, respectively. The numbers are protein amino acid positions. B: Structure of PIAS1. SAF (sca¡old-associated factor)-box and
RING ¢nger-like domain of the protein are denoted as gray and black boxes, respectively. Binding regions for the androgen receptor, p53 and
IE2(in this work) are also indicated. C: Yeast transformants containing the two plasmids encoding GAL4-DB and GAL4-A domain fusions
were streaked on a growth plate lacking Trp and Leu or on a plate lacking Trp, Leu, and His but containing 15 mM of 3-amino triazole
(3-AT), an inhibitor of the HIS3 gene product, and grown at 30‡C. IE2(87^542) lacking the two activation domains was used in this experi-
ment. D: Binding of wild-type or mutant IE2 with SUMO-1 or PIAS1. Yeast transformants containing the indicated GAL4-DB/IE2 fusions
and either GAL4-A only, GAL4-A/SUMO-1, or GAL4-A/PIAS1 were grown and the L-galactosidase activities of the transformants were mea-
sured as described in Section 2.
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previously described [9]. Slides were examined and photographed
under a Zeiss Axiopgoto2 microscope.
For immunoblot analysis, DNA-transfected cells were washed with
phosphate-bu¡ered saline and total extracts were prepared by boiling
the cell pellets in sodium dodecyl sulfate (SDS) loading bu¡er. Equal
amounts of the clari¢ed cell extracts were separated on a SDS^8%
polyacrylamide gel, and subjected to the standard enhanced chemilu-
minescence system procedure (Amersham).
2.5. Luciferase reporter assay
For luciferase reporter assays, transfected cells were collected and
lysed using three freeze^thaw steps in 200 Wl of 0.25 M Tris^HCl (pH
7.9) plus 1 mM dithiothreitol. Subsequent procedures were as previ-
ously described [9]. A TD-20/20 luminometer (Turner Designs) was
used for the 10-s assay of the photons produced (measured in relative
light units).
3. Results and discussion
3.1. Interaction of PIAS1 with HCMV IE2
In an attempt to identify cellular proteins interacting with
HCMV IE2 protein, we screened a cDNA library prepared
from human B lymphocyte using the yeast two-hybrid system
[9]. Although HCMV does not infect B lymphocyte, this li-
brary was successfully used to isolate IE2-binding cellular
partners [8,9]. A region of the IE2 protein spanning amino
acid position 87^542, lacking both the N- and C-terminal
transactivation domains was used as bait (Fig. 1A). One of
the positive clones contained the C-terminal domain of PIAS1
(amino acids 416^651) (Fig. 1B). When the full length PIAS1
protein (amino acids 1^651) was tested for IE2 binding, it was
found to bind to IE2 with the same strength as the C-terminal
domain (461^651) of PIAS1, as judged by the ability of yeast
cells to grow in selection plates (Fig. 1C). The interaction
between p53 and SV40 large T-Ag was used as a positive
control. This result suggests that the C-terminal domain of
PIAS1 (from 461 to 651) participates in IE2 binding.
IE2 was shown to bind to both SUMO-1 and Ubc9 by
yeast two-hybrid interaction assays, and to be covalently
modi¢ed by SUMO-1 [8,9]. Two major sumoylation sites of
IE2 were mapped to Lys residues at amino acid positions 175
and 180, and IE2 was also shown to bind directly to SUMO-1
moieties in in vitro binding assays. The interaction of IE2 with
Ubc9 in yeast was mainly indirect because the sumoylation-
defective mutant IE2(K175/180R) containing Lys to Arg sub-
stitutions at residues 175 and 180 almost lost its ability to
bind to Ubc9 [9]. To investigate whether sumoylation of IE2
is also involved in PIAS1 binding, two-hybrid interaction as-
says of PIAS1 with the sumoylation-defective mutant IE2
proteins were conducted (Fig. 1D). Interactions of SUMO-1
with the mutant IE2 proteins were used as controls. We found
that the interaction of PIAS1 with IE2(K175/180R) was re-
duced to 50% of wild-type IE2, suggesting that the sumoyla-
tion of IE2 is required for e⁄cient PIAS1 binding. A motif
that is involved in direct SUMO contact lies between positions
200 and 208 of IE2 [9]. Substitution mutations of Ser at 203 to
Ala in both intact IE2 and IE2(K175/180R) backgrounds did
not a¡ect the interaction with PIAS1, though they slightly lost
the ability to bind to SUMO-1. We also found that, unlike
SUMO-1, PIAS1 interacted with the C-terminal domain of
IE2(290^542), which is involved in both self-interaction and
in interactions with many cellular proteins (Fig. 1D).
We further investigated whether the smaller C-terminal re-
gions of IE2 bind to PIAS1. As was found in yeast interaction
assays, both IE2(313^542) and IE2(346^542) bound to PIAS1
at around the same strength as they bound to IE2(290^542)
(Fig. 2A). We con¢rmed the interaction of PIAS1 with the C-
terminal domains of IE2 by using in vitro binding assays with
glutathione-S-transferase fusion proteins. When the GST
fusion proteins containing IE2(290^542), IE2(313^542) or
IE2(346^542) were puri¢ed from Escherichia coli and bound
to in vitro [35S]-labeled PIAS1 protein, all GST-IE2 proteins
bound to PIAS1 with a strength similar to the interaction of
Fig. 2. Interaction of the C-terminal domains of IE2 with PIAS1.
A: Interaction of the C-terminal domains of IE2 with PIAS1 in
yeast two-hybrid assays. L-Galactosidase production by yeast trans-
formants containing plasmids encoding GAL4-DB/IE2 fusion, and
GAL4-A/PIAS1 or GAL4-A alone was determined by using X-gal
¢lter assays, as described in Section 2. Two independent yeast trans-
formants were assayed for each combination of interaction. B: In
vitro binding assay of PIAS1 with GST fusion proteins. The GST
or GST fusion proteins immobilized to glutathione-Sepharose beads
were incubated with [35S]methionine-labeled full length PIAS1. One-
¢fth of the labeled PIAS1 proteins used in each binding reaction
were loaded as an input control. The bound proteins were fraction-
ated and visualized by autoradiography. C: The relative sizes and
amounts of the GST or of GST fusion proteins used in the assay.
One-tenth of the GST or GST fusion proteins used in B were frac-
tionated and stained with Coomassie blue. Note that the less e⁄-
cient pull-down of 35S-PIAS1 by GST-IE2(312^542) was due to the
use of lower amount of GST-IE2(312^542) than other GST-IE2 fu-
sion proteins.
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GST-SUMO-1 with PIAS1 (used as a control) (Fig. 2B,C).
Although we could not test whether the full length IE2 also
binds to PIAS1 in this assay due to the low expression level of
the GST-IE2(full length) fusion protein in E. coli, our results
suggest that IE2 may bind to PIAS1 through the C-terminal
domain of IE2, which is well conserved among equivalent
proteins of betaherpesviruses [32].
3.2. PIAS1 is colocalized with IE2
The nuclear dot-like distribution pattern of exogenous
PIAS1 in U2OS cell line has been previously reported [33].
We also found that £ag-PIAS1 was distributed as a mixture of
nuclear di¡use and punctate forms in Vero cells (Fig. 3a,d). In
double-labeled IFA, the punctate forms of PIAS1 were local-
ized adjacent to endogenous PML in PODs, suggesting that,
like IE2 [6,7], a subset of PIAS1 is localized in the vicinity of
PODs (Fig. 3a^f).
We further investigated whether PIAS1 colocalizes with IE2
in cotransfected cells. In double-labeled IFA of Vero cells
cotransfected with £ag-PIAS1 and IE2, both proteins were
e⁄ciently colocalized in nuclear punctate forms (Fig. 3g^l).
Although we could not detect the colocalization of IE2 with
endogenous PIAS1 in virus-infected cells due to the lack of
antibody that detects endogenous PIAS1 in permissive HF
cells, this IFA result suggests that IE2 may be associated
with PIAS1 within the nucleus.
Fig. 3. Colocalization of PIAS1 with IE2. Vero cells were transfected with a plasmid encoding £ag-PIAS1 alone (a^f) or cotransfected with
plasmids encoding £ag-PIAS1 and HA-IE2 (g^l). At 36 h after transfection, cells were ¢xed with formaldehyde and doubl-labeled IFA was car-
ried out with mouse MAb M2 for £ag-PIAS1 and either rabbit PAb PML(C) for endogenous PML (a^f) or FITC-labeled rat MAb (3F10)
against HA-IE2 (g^l). Two di¡erent images were shown for each IFA. FITC-labeled or rhodamine-red X-conjugated anti-mouse IgG and rho-
damine-red X-conjugated anti-rabbit IgG were used for visualization.
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3.3. PIAS1 enhances the sumoylation of IE2 in cotransfected
cells
Because members of the PIAS protein family are known to
act as SUMO E3 ligases, we investigated whether PIAS1 en-
hances the sumoylation of IE2. In a preliminary experiment,
293T cells were transfected with either wild-type IE2 or su-
moylation-defective IE2(K175/180R) alone, or cotransfected
together with £ag-SUMO-1, and immunoblot analysis of total
extracts was carried out using mouse MAb8131 against IE2
(Fig. 4A). The results showed that the expression of wild-type
IE2 alone produced a slowly migrating single SUMO-modi-
¢ed IE2 form as well as the normal 86-kDa form and, when
coexpressed with SUMO-1, the levels of the single or double
SUMO-modi¢ed forms of wild-type IE2 were markedly in-
creased. However, as expected IE2(K175/180R) did not pro-
duce any sumoylated forms, con¢rming that Lys residues at
positions 175 and 180 are the only sumoylation sites in DNA-
transfected 293T cells.
To investigate e¡ect of PIAS1 on the sumoylation of IE2,
we carried out similar cotransfection assays in the presence of
SRT-tagged PIAS1. When IE2 was coexpressed with both
£ag-SUMO-1 and SRT-PIAS1, the sumoylation level of IE2
was markedly increased by PIAS1 (Fig. 4B, upper panel). To
investigate whether the positive e¡ect of PIAS1 on the sumoy-
Fig. 4. E¡ect of PIAS1 on IE2 sumoylation in cotransfection assays.
A: Sumoylation of IE2 in transiently DNA-cotransfected cells. 293T
cells were cotransfected with plasmids encoding wild-type IE2,
IE2(K175/180R), or £ag-SUMO-1 as indicated. At 48 h after trans-
fection extracts were prepared as described in Section 2. Equal
amounts of cell extracts were separated on a SDS^8% polyacryl-
amide gel and immunoblot analysis was performed with MAb 8131
for IE2. B: E¡ect of PIAS1 on the sumoylation levels of IE2 and
cellular proteins. 293T cells were cotransfected with plasmids encod-
ing SRT-tagged wild-type or C351S mutant PIAS1, £ag-SUMO-1,
or IE2 as indicated. Forty-eight hours after transfection extracts
were prepared and immunoblot analysis was carried out as de-
scribed in A with MAb 8131 for IE2 (top panel). The same blot
was stripped and the second and third immunoblot analyses were
carried out with MAb against SRT-PIAS1 (middle panel) and with
MAb M2 for £ag-SUMO-1-conjugated proteins (bottom panel), re-
spectively.
Fig. 5. E¡ects of PIAS1 on IE2-mediated transactivation. A: E¡ects
of wild-type or C351S mutant PIAS1 proteins on the IE2-mediated
transactivation of the HCMV polymerase promoter. Vero cells were
cotransfected with 0.2 Wg of reporter plasmid (pPol-LUC) contain-
ing a HCMV UL54(Pol)-luciferase reporter gene and 0.2 Wg of plas-
mid encoding IE2, 0.2 Wg of plasmid encoding SUMO-1, and 0.02
or 1.0 Wg of plasmid encoding either wild-type or the C351S mutant
PIAS1 proteins. All samples for reporter assays were made up to
the same total amount of DNA with empty vectors. At 30 h after
transfection, total cell extracts were prepared and assayed for lucif-
erase activity. Luciferase activities are indicated as fold activation
over the basal level of each reporter gene. The results shown are the
mean values and standard errors of three independent experiments.
B: U373-SUMO-1 cells were initially transfected with 5 Wg of empty
vector or plasmid encoding either wild-type or C351S mutant
PIAS1. At 24 h after transfection, the cells were mock-infected or
super-infected with recombinant HCMV(Pol-Luc) at an M.O.I. of
1.0. After further incubation for 24 h, cells were harvested for the
assay of luciferase activity. The results shown are the average of
two independent experiments (top). To see the expression levels of
transfected PIAS1 proteins in the cell extracts assay, equal amounts
of the same cell extracts from an experiment were separated on a
SDS^8% polyacrylamide gel and immunoblot analysis was per-
formed with anti-SRT antibody. Loading of the equal amounts of
proteins was also veri¢ed by immunoblot analysis with anti-L-actin
antibody (bottom). C: E¡ect of IE2 sumoylation sites on the coop-
erative augmentation of the IE2-mediated transactivation of the cel-
lular cyclin E promoter by PIAS1. Vero cells were cotransfected
with 0.3 Wg of reporter plasmid, pE(3207)-LUC, containing a cellu-
lar cyclin E-luciferase reporter gene and 0.05 or 0.2 Wg of plasmid
encoding PIAS1 and 0.05 Wg of plasmid encoding wild-type or
K175/180R mutant IE2 proteins (left), or with 0.3 Wg of reporter
plasmid and 0.05 Wg of IE2 and 0.2 Wg of wild-type or C351S mu-
tant PIAS1 (right). At 30 h after transfection, total cell extracts
were prepared and assayed for luciferase activity as described in A.
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lation of IE2 is indeed due to its E3 ligase activity, we used a
mutant PIAS1(C351S) that contained a Cys to Ser substitu-
tion at position 351, which disrupts the RING ¢nger-like do-
main of PIAS1 and lacks SUMO E3 ligase activity [16]. The
results showed that PIAS1(C351S) failed to enhance the su-
moylation of IE2, thus demonstrating that the sumoylation
level of IE2 is enhanced by the E3 ligase activity of PIAS1.
The expressions of both wild-type and mutant PIAS1 were
con¢rmed by immunoblot analysis of the same blot with
anti-SRT antibody, although PIAS1(C351S) appeared to be
less stable than the wild-type protein (Fig. 4B, middle panel).
The general SUMO E3 ligase activity of the wild-type PIAS1,
but not of PIAS(C351S), on cellular proteins were con¢rmed
by immunoblotting of the same blot with anti-£ag antibody,
which detects all cellular proteins modi¢ed by ectopically ex-
pressed £ag-SUMO-1 (Fig. 4B, bottom panel).
3.4. E¡ect of PIAS1 on IE2-mediated transactivation
To investigate whether the interaction of PIAS1 with IE2
a¡ects the transactivation function of IE2, we carried out
target reporter gene assays. The transcactivation activity of
IE2 was well demonstrated in Vero cells [9,34]. Vero cells
were cotransfected with a target reporter plasmid expressing
luciferase under the control of the HCMV UL54 (polymerase)
promoter (Pol-LUC) and e¡ector plasmids expressing IE2,
SUMO-1 and either wild-type PIAS1 or the C351S mutant
PIAS1 (Fig. 5A). IE2 alone activated the Pol promoter by
13-fold, and the coexpression of IE2 with SUMO-1 enhanced
the activation of Pol promoter by up to 23-fold. When IE2
was coexpressed with both SUMO1 and PIAS1, IE2-mediated
transactivation was increased by up to 40-fold by wild-type
PIAS1, but not by the C351S mutant, in a dose-dependent
manner (Fig. 5A). This result suggests that PIAS1 may en-
hance the transactivation activity of IE2 by increasing the
sumoylation level of IE2.
To address whether PIAS1 enhances the IE2-mediated
transactivation of viral Pol promoter in virus-infected cells,
the permissive U373 cells, which constitutively express
SUMO-1 (U373-SUMO-1) [28], were initially transfected
with wild-type or C351S mutant PIAS1, and subsequently
super-infected with a recombinant HCMV(Pol-LUC), con-
taining the extragenic Pol-LUC reporter gene [29]. The result
of luciferase assay showed that wild-type PIAS1, but not
C351S mutant, enhanced the activation of Pol promoter by
two-fold in HCMV-infected cells (Fig. 5B, top). Although
immunoblot analysis of the same extracts with anti-SRT anti-
body showed lower expression level of C351S mutant than the
wild-type protein (Fig. 5B, bottom), the Pol-LUC activity in
cells that received C351S protein was not increased at all
compared to control cells that did not receive any PIAS1
protein. This indicates that the lack of positive e¡ect by
C351S mutant is not due to its low expression level. Because
PIAS1 did not activate the Pol promoter at all in assays with
Pol-LUC reporter gene in cotransfected U373 cells (data not
shown), this result suggests that PIAS1 may enhance the IE2-
mediated transactivation of Pol promoter in virus-infected
cells.
IE2 has been shown to directly bind to and activate the
cyclin E promoter in transient reporter assays [35]. We pre-
viously showed that the coexpression of both SUMO and
Ubc9 enhances the IE2-mediated activation of the cyclin E
promoter and that this process requires the sumoylation sites
of IE2 [9]. To further investigate whether PIAS1 has a similar
e¡ect, target reporter gene assays were carried out with a
plasmid expressing luciferase under the control of the cyclin
E promoter. The results obtained showed that PIAS1 en-
hanced the IE2-mediated transactivation of the cyclin E pro-
moter in a dose-dependent manner and this augmentation
requires the intact sumoylation sites of IE2, and that the
C351S mutant PIAS1 did not a¡ect the activation of cyclin
E promoter by IE2 (Fig. 5C). These results suggest that
PIAS1 regulates the transcriptional activation function of
IE2 through sumoylation.
In domain mapping experiments, two major sumoylation
sites (Lys residues) of IE2 at position 175 and 180 were re-
quired intact for e⁄cient PIAS1 binding, although the C-ter-
minal domain that lacks these sumoylation sites supported a
binding to PIAS1 in vitro. This result suggests that both in-
direct binding through SUMO moieties conjugated to IE2 and
direct binding through the C-terminal domain may contribute
to IE2:PIAS1 interaction. The former is consistent with the
¢nding that PIAS1 has an ability to tether other sumoylated
proteins in a non-covalent fashion [27]. In addition to the
apparent SUMO E3 ligase activity toward IE2, this SUMO
tethering activity of PIAS1 may regulate the intracellular lo-
calization or stability of IE2. Indeed, our results show that
both IE2 and PIAS1 colocalized in punctate forms and that
the steady state levels of IE2 appear to be increased in the
presence of PIAS1 in cotransfected cells.
Our study shows that PIAS enhanced the IE2-mediated
transactivation of both the viral polymerase and the cellular
cyclin E promoters in a SUMO E3 ligase-dependent manner.
Although one report questioned the role of IE2 on cyclin E
level increases in HCMV-infected cells [36], several reports
have demonstrated that IE2 transfection upregulates the cy-
clin E promoter, cyclin E mRNA levels, and cyclin E-associ-
ated kinase activity [35,37,38]. The activation of cyclin E ap-
pears to be a viral strategy to force cells to enter the S-phase,
which facilitates a more favorable environment for HCMV
replication [39]. Our results suggest that the enhanced sumoy-
lation of IE2 by PIAS1 may contribute in part to the dysreg-
ulation of the cell cycle to facilitate the progress of HCMV
infection. Given that IE2 was found to be very e⁄ciently
sumoylated in an in vitro system containing both E1 and
E2, but not E3 [9], the strong interaction between IE2 and
PIAS1 may re£ect more than binding between an enzyme and
a substrate. However, whether IE2 regulates the function of
PIAS1 as a SUMO E3 ligase or as a transcriptional coactiva-
tor, remains to be further investigated.
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